StrokEnomics

StrokEnomics: Solving the economic piece of the stroke care puzzle

Allied with its goal to develop innovative ischaemic and haemorrhagic stroke treatment is Stryker’s commitment to demonstrate the economic value of these treatments in a way that matters most to the physician. This is a part of the underlying principle for StrokEnomics, the data-driven health economics programme developed by Stryker. Through StrokEnomics, Stryker is committed to delivering strategies around health economic analysis and funding solutions that understand the challenges inherent in modern stroke care.

StrokEnomics uses powerful economic and clinical data to enhance both patient access and quality of care

STROKENOMICS IS A PROGRAMME

designed to enhance patient access and quality of care around the world. Using economic and clinical data, Stryker is able to help healthcare professionals to create tailored solutions that may improve patient access and make care more efficient.

Armed with the highest level of clinical and economic data, StrokEnomics can strategically navigate barriers, helping to ensure that cutting-edge neurovascular care is accessible to eligible patients. The first consideration is the evidence from the real world and randomised clinical trials. Thereafter, the economic considerations of a treatment come into view—it begins with a cost-effectiveness analysis, offering a comprehensive evaluation of the cost and effectiveness of two treatments to find the best-health, lowest-cost option. Allied to this is a budget impact analysis, assessing the economic impact of treating all eligible patients.

Putting this into practice—current approaches for patients suffering from ischaemic stroke and arriving up to 24 hours after symptom onset include mechanical thrombectomy with a stent retriever in combination with intravenous tissue plasminogen activator (IV tPA) or IV t-PA alone. The two options are considered against both a cost and effectiveness metric, considering quality-adjusted life-year data from randomised trials comparing the approaches—including DAWN —and the results from both metrics are extrapolated across the patient’s lifetime horizon.

Although there is a higher cost associated with the stent retriever itself, this can be offset through the savings that result from lower long-term care costs due to improved outcomes—even for this late arrival patients. Thus, using StrokEnomics, it is possible to demonstrate that through a particular approach further benefits can be achieved, as well as a reduction in cost, compared to the alternative treatment in a patient’s lifetime.

Cost-effectiveness analysis

We comparatively evaluate the cost and the effectiveness of two treatments to identify the best-health, lowest-cost option.

Budget impact analysis

We assess the economic impact of treating eligible patients with a newly adopted intervention, compared with a current intervention.

Budget pro-forma

We evaluate the financial impact of adding a stroke program based on hospital-specific data – immediately and into the future.

Cost-minimisation analysis

To identify potential cost savings, we comparatively evaluate the cost of alternative interventions with equivalent efficacy.

Cost benefit analysis

For a new treatment adoption, we demonstrate the economic benefits and how its adoption can improve patient access.

Together with our customers, we are driven to make healthcare better.

Stryker is one of the world’s leading medical technology companies, but it’s not only because of the products we make. It’s also about the services, programs and partnerships we’ve established to ensure we’re with our customers all the way.

This document is intended solely for the use of healthcare professionals.

A physician must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that physicians be trained in the use of any particular product before using it in a procedure. The information presented is intended to demonstrate the breadth of Stryker product offerings. A physician must always refer to the package insert, product label and/or instructions for use before using any Stryker product. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Stryker representative if you have questions about the availability of Stryker products in your area. Stryker or its affi liated entities own, use, or have applied for the following trademarks or service marks: AXS Catalyst, AXS Vecta, Nano, SKILL Assist, SL-10, StrokEnomics, Stryker, Surpass Evolve, Synchro SELECT, Target, Target XL, Trevo, Trevo NXT, XT-27. All other trademarks are trademarks of their respective owners or holders. The absence of a product, feature, or service name, or logo from this list does not constitute a waiver of Stryker’s trademark or other intellectual property rights concerning that name or logo. Copyright © 2021 Stryker AP-003473 v1.0 | Page 12 of 12